The treatment of ALS with SPG302 entered a new phase in 2025. This drug, developed by Spinogenix, can halt or even reverse the progression of the disease by repairing damaged synapses.
Confirmation of wide access to SPG302 for the treatment of ALS
The U.S. Food and Drug Administration (FDA) has granted approval for the Expanded Access program for the drug SPG302. This allows eligible patients to have early access to this treatment method.
How does SPG302 help in the treatment of ALS?
SPG302 is an oral medication designed to rebuild neural synapses. This means that unlike previous treatments, it restores nerve function instead of merely slowing down the progression of the disease.
The benefits of the SPG302 drug for ALS patients
- ✅ Daily consumption in pill form
- ✅ Repairing damaged synapses
- ✅ Potential improvement in cognitive and motor performance
- ✅ Without the need for injections or special equipment
In which countries are clinical trials being conducted?
Currently, SPG302 is undergoing clinical trials in the United States and Australia. Given the approval for expanded access, certain patients can benefit from this drug before its official release.
The future outlook
If the tests are completely successful, the treatment of ALS with SPG302 may become the first restorative treatment for this disease. Experts hope that this new approach will pave the way for a transformation in the treatment of neurological diseases.
📌 Conclusion
ALS treatment is a real hope for the future of patients. This drug not only preserves the function of nerve cells but also has the ability to regenerate them.
Related topics: Symptoms and initial diagnosis of ALS